Kilitch Drugs India Ltd approves proposed full divestment of Ethiopian subsidiary for US$14 million and conversion of up to ₹57 crore of debt into equity
- Both transactions are subject to regulatory approvals and compliance.
- Q2 FY27 consolidated revenue was ₹50.22 crore, up 14.3% year on year; net profit was ₹1.41 crore, down 82.4%.
- The board approved unaudited results for the quarter and half year ended 30 September 2026; the auditor’s review conclusion was unmodified.